Opaleye Management as of Dec. 31, 2015
Portfolio Holdings for Opaleye Management
Opaleye Management holds 53 positions in its portfolio as reported in the December 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical (RARE) | 5.2 | $12M | 110k | 112.18 | |
| Axogen (AXGN) | 4.4 | $11M | 2.1M | 5.00 | |
| Fibrogen (FGEN) | 4.1 | $9.9M | 325k | 30.47 | |
| Geron Corporation (GERN) | 3.7 | $8.8M | 1.8M | 4.84 | |
| Medgenics | 3.5 | $8.4M | 1.4M | 6.02 | |
| Imprimis Pharmaceuticals | 3.5 | $8.4M | 1.2M | 6.93 | |
| Ophthotech | 3.5 | $8.2M | 105k | 78.53 | |
| Protalix Biotherapeutics Inc note 4.500% 9/1 | 3.5 | $8.3M | 8.1M | 1.02 | |
| Ariad Pharmaceuticals | 3.4 | $8.2M | 1.3M | 6.25 | |
| Eagle Pharmaceuticals (EGRX) | 3.1 | $7.5M | 85k | 88.67 | |
| Inotek Pharmaceuticals Corp conv | 3.1 | $7.3M | 645k | 11.33 | |
| Blueprint Medicines (BPMC) | 3.0 | $7.2M | 275k | 26.34 | |
| Cara Therapeutics (CARA) | 3.0 | $7.2M | 427k | 16.86 | |
| Codexis (CDXS) | 2.8 | $6.8M | 1.6M | 4.23 | |
| Retrophin | 2.8 | $6.7M | 345k | 19.29 | |
| Relypsa | 2.6 | $6.2M | 220k | 28.34 | |
| Cempra | 2.6 | $6.2M | 200k | 31.13 | |
| Sage Therapeutics (SAGE) | 2.4 | $5.8M | 100k | 58.30 | |
| Supernus Pharmaceuticals (SUPN) | 2.4 | $5.6M | 420k | 13.44 | |
| DepoMed | 2.3 | $5.4M | 300k | 18.13 | |
| Adamas Pharmaceuticals | 2.2 | $5.4M | 190k | 28.32 | |
| AMAG Pharmaceuticals | 1.9 | $4.5M | 150k | 30.19 | |
| Tonix Pharmaceuticls | 1.8 | $4.3M | 565k | 7.67 | |
| Avinger | 1.8 | $4.3M | 190k | 22.71 | |
| Affimed Therapeutics B V | 1.8 | $4.2M | 595k | 7.12 | |
| Foamix Pharmaceuticals | 1.7 | $4.1M | 500k | 8.11 | |
| Cytrx | 1.6 | $3.8M | 1.4M | 2.65 | |
| La Jolla Pharmaceutical | 1.6 | $3.8M | 140k | 27.00 | |
| Tg Therapeutics (TGTX) | 1.5 | $3.6M | 300k | 11.93 | |
| Intec Pharma | 1.4 | $3.4M | 630k | 5.36 | |
| Amarin Corporation (AMRN) | 1.4 | $3.3M | 1.8M | 1.89 | |
| Neurocrine Biosciences (NBIX) | 1.3 | $3.1M | 55k | 56.56 | |
| Flamel Technologies | 1.3 | $3.1M | 250k | 12.21 | |
| Agile Therapeutics | 1.2 | $2.9M | 300k | 9.76 | |
| Corium Intl | 1.2 | $2.9M | 355k | 8.12 | |
| Trillium Therapeutics, Inc. Cmn | 1.1 | $2.6M | 210k | 12.61 | |
| Xenon Pharmaceuticals (XENE) | 1.0 | $2.4M | 300k | 8.04 | |
| XOMA CORP Common equity shares | 0.9 | $2.3M | 1.7M | 1.33 | |
| Zogenix | 0.9 | $2.2M | 150k | 14.74 | |
| Alder Biopharmaceuticals | 0.9 | $2.1M | 65k | 33.03 | |
| Nabriva Therapeutics | 0.9 | $2.1M | 220k | 9.62 | |
| Auris Med Hldg | 0.8 | $1.8M | 375k | 4.89 | |
| Tenax Therapeutics | 0.7 | $1.8M | 540k | 3.28 | |
| Cynapsus Therapeutics | 0.7 | $1.7M | 110k | 15.29 | |
| Accelr8 Technology | 0.7 | $1.6M | 75k | 21.49 | |
| Cellectis S A (CLLS) | 0.7 | $1.6M | 50k | 31.04 | |
| Macrogenics (MGNX) | 0.5 | $1.1M | 35k | 30.97 | |
| Vitae Pharmaceuticals | 0.4 | $1.1M | 59k | 18.10 | |
| Immunomedics | 0.4 | $890k | 290k | 3.07 | |
| Achaogen | 0.3 | $718k | 125k | 5.74 | |
| Sangamo Biosciences (SGMO) | 0.2 | $548k | 60k | 9.13 | |
| Evoke Pharma | 0.2 | $429k | 130k | 3.30 | |
| Biolinerx Ltd-spons | 0.1 | $325k | 250k | 1.30 |
